ヒト組換えDNAの世界市場

世界のヒト組換えDNAの市場規模は、2022年までに3,487億米ドルに達するとみられています。

同市場は、2022年～2027年の予測期間中に7.3%のCAGRで拡大し、2027年には4,969億米ドルを超えると予測されています。

当レポートでは、世界のヒト組換えDNA市場について調査し、市場の概要とともに、製品タイプ別、エンドユーザー別、地域別動向、COVID-19の影響、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 まとめとハイライト

第3章 概要

第4章 COVID-19パンデミックの影響

第5章 市場力学

• 市場の促進要因
• 市場の抑制要因
• 市場の機会

第6章 市場の内訳、製品タイプ別

• ヒトタンパク質の置換
• 人間の疾患のための治療薬
• ワクチン
• ワクチンタイプ

第7章 市場の内訳、エンドユーザー別

• バイオテクノロジー業界、製薬産業
• 学術研究機関

第8章 市場の内訳、地域別

• 地域別の世界市場
• 北米
• 欧州
• アジア太平洋
• その他の地域

第9章 競合情勢

第10章 企業プロファイル

• ABBVIE INC.
• ALEXION PHARMACEUTICALS
• AMGEN INC.
• ELI LILLY
• MERCK & CO. INC.
• SANOFI S.A.
• TAKEDA PHARMACEUTICAL CO LTD.

List of Tables

• Summary Table : Global Market for Human Recombinant DNA, by Region, Through 2027
• Table 1 : Estimated World Population and Annual Growth, by Selected Age Group, Through 2030
• Table 2 : Cancer Statistics Across Major Asian Countries, by Cancer Site/Type, 2020
• Table 3 : Global Human Recombinant DNA Market, by Product Type, Through 2027
• Table 4 : Global Market for Human Protein Replacements, by Region, Through 2027
• Table 5 : Global Market for Therapeutic Agents for Human Diseases, by Region, Through 2027
• Table 6 : Vaccine Types
• Table 7 : Global Market for Vaccines, by Region, Through 2027
• Table 8 : Global Market for Human Recombinant DNA, by End User, Through 2027
• Table 9 : Global Market for Human Recombinant DNA in the Biotechnology and Pharmaceutical Industry, by Region, Through 2027
• Table 10 : Global Market for Human Recombinant DNA in Research Laboratories and Academic Institutes, by Region, Through 2027
• Table 11 : Global Market for Human Recombinant DNA, by Region, Through 2027
• Table 12 : North American Market for Human Recombinant DNA, by Product Type Through 2027
• Table 13 : North American Market for Human Recombinant DNA, by End User, Through 2027
• Table 14 : North American Market for Human Recombinant DNA, by Country, Through 2027
• Table 15 : European Market for Human Recombinant DNA, by Product Type, Through 2027
• Table 16 : European Human Recombinant DNA Market, by End User, Through 2027
• Table 17 : European Market for Human Recombinant DNA, by Country, Through 2027
• Table 18 : Asia-Pacific Market for Human Recombinant DNA, by Product Type, Through 2027
• Table 19 : Asia-Pacific Human Recombinant DNA Market, by End User, Through 2027
• Table 20 : Asia-Pacific Market for Human Recombinant DNA, by Country, Through 2027
• Table 21 : Japan: Total Number of New Cancer Cases in Both Genders, 2020
• Table 22 : RoW Market for Human Recombinant DNA, by Product Type, Through 2027
• Table 23 : RoW Market for Human Recombinant DNA, by End User, Through 2027
• Table 24 : Leading Market Players in the Human Recombinant DNA Market Ecosystem
• Table 25 : AbbVie Inc.: Business Segments
• Table 26 : AbbVie Inc.: Financial Performance, Through 2020
• Table 27 : Amgen: Financial Performance, Through 2020
• Table 28 : Eli Lilly: Business Segments
• Table 29 : Eli Lilly: Financial Performance, 2018-2020
• Table 30 : Sanofi: Business Segments
• Table 31 : Sanofi: Financial Performance, 2018-2020

List of Figures

• Summary Figure A : Global Market for Human Recombinant DNA, by Region, 2020-2027
• Summary Figure B : Global Market Shares of Human Recombinant DNA, by Region, 2021
• Figure 1 : Global Market Shares of Human Recombinant DNA, by Product Type, 2021
• Figure 2 : Global Market for Human Recombinant DNA, by Product Type, 2020-2027
• Figure 3 : Global Market for Human Protein Replacements, 2020-2027
• Figure 4 : Global Market for Therapeutic Agents for Human Diseases, 2020-2027
• Figure 5 : Evolution of Vaccine Technologies
• Figure 6 : Global Market for Vaccines, 2020-2027
• Figure 7 : Global Market Shares of Human Recombinant DNA, by End User, 2021
• Figure 8 : Global Market for Human Recombinant DNA, by End User, 2020-2027
• Figure 9 : Global Market for Human Recombinant DNA in the Biotechnology and Pharmaceutical Industry, 2020-2027
• Figure 10 : Global Market for Human Recombinant DNA in Research Laboratories and Academic Institutes, 2020-2027
• Figure 11 : Global Market Shares of Human Recombinant DNA, by Region, 2021
• Figure 12 : North American Market Shares of Human Recombinant DNA, by Product Type, 2021
• Figure 13 : North American Market Shares of Human Recombinant DNA, by End User, 2021
• Figure 14 : North American Market Shares of Human Recombinant DNA, by Country, 2021
• Figure 15 : U.S. Market for Human Recombinant DNA, 2020-2027
• Figure 16 : Canadian Market for Human Recombinant DNA, 2020-2027
• Figure 17 : European Market Shares of Human Recombinant DNA, by Product Type, 2021
• Figure 18 : European Human Recombinant DNA Market, Market Shares, by End User, 2021
• Figure 19 : European Market Shares of Human Recombinant DNA, by Country, 2021
• Figure 20 : Geriatric Population in Germany, 2000-2030
• Figure 21 : German Market for Human Recombinant DNA, 2020-2027
• Figure 22 : U.K. Market for Human Recombinant DNA, 2020-2027
• Figure 23 : French Market for Human Recombinant DNA, 2020-2027
• Figure 24 : Italian Market for Human Recombinant DNA, 2020-2027
• Figure 25 : Spanish Market for Human Recombinant DNA, 2020-2027
• Figure 26 : Rest of Europe Market for Human Recombinant DNA, 2020-2027
• Figure 27 : Asia-Pacific Market Shares of Human Recombinant DNA, by Product Type, 2021
• Figure 28 : Asia-Pacific Human Recombinant DNA Market, Market Shares, by End User, 2021
• Figure 29 : Asia-Pacific Market Shares of Human Recombinant DNA, by Country, 2021
• Figure 30 : New Cancer Cases in China, 2020
• Figure 31 : Distribution of New Cancer Cases in China, 2020
• Figure 32 : Chinese Market for Human Recombinant DNA, 2020-2027
• Figure 33 : Japanese Market for Human Recombinant DNA, 2020-2027
• Figure 34 : Indian Market for Human Recombinant DNA, 2020-2027
• Figure 35 : Rest of Asia-Pacific Market for Human Recombinant DNA, 2020-2027
• Figure 36 : New Cancer Cases in Africa, 2020
• Figure 37 : RoW Market Shares of Human Recombinant DNA, by Product Type, 2021
• Figure 38 : RoW Market Shares of Human Recombinant DNA, by End User, 2021
• Figure 39 : AbbVie Inc.: Net Revenue, by Business Segment, 2020
• Figure 40 : AbbVie Inc.: Net Revenue, by Region, 2020
• Figure 41 : Amgen: Total Sales, by Product, 2020
• Figure 42 : Amgen: Total Revenue, by Region, 2020
• Figure 43 : Eli Lilly: Total Sales, by Product Segment, 2020
• Figure 44 : Eli Lilly: Total Revenue, by Region, 2020
• Figure 45 : Sanofi: Net Sales, by Business Segment, 2020
• Figure 46 : Sanofi: Net Sales, by Region, 2020

Highlights:

The global human recombinant DNA market should reach $348.7 billion by 2022 and more than $496.9 billion by 2027, with a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2022-2027.

North American human recombinant DNA market should reach $150.8 billion by 2022 and more than $191.7 billion by 2027, with a CAGR of 4.9% during the forecast period of 2022-2027.

Asia-Pacific human recombinant DNA market should reach $86 billion by 2022 and more than $136.2 billion by 2027, with a CAGR of 9.6% during the forecast period of 2022-2027.

Report Scope:

This report highlights the current and future market potential for human recombinant DNA and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, trends and key players in the market. The report also provides market projections from 2022 through 2027. An in-depth discussion of strategic alliances, industry structures, competitive dynamics, and market forces are also provided.

Report Includes:

• 24 data tables and 8 additional tables
• An overview of the global market for human recombinant DNA
• Estimation of the market size and analyses of global market trends, with data from 2020, 2021 with projections of compound annual growth rates (CAGRs) through 2026
• Highlights of the market potential for human recombinant DNA, based on product, application, and region
• Coverage of history and future of human recombinant DNA, and latest technological advancements of the industry
• Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
• Coverage of regulatory landscape, product recalls, pipeline products, and discussion on future perspective, strategies, and developments of the industry
• Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and a relevant patent analysis
• Company profiles of major players within the industry AbbVie Inc., Amgen Inc., Eli Lilly, Sanofi

Table of Contents

Chapter 1 Introduction

• Introduction
• Study Goals and Objectives
• Reasons for Doing the Study
• Intended Audience
• Scope and Format
• Methodology
• Market Estimates
• Information Sources
• Geographical Breakdown
• Analyst's Credentials
• BCC Custom Research
• Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

• Homologous Recombination (HR)
• Targets for Cancer Therapy

Chapter 4 Impact of COVID-19 Pandemic

Chapter 5 Market Dynamics

• Market Drivers
• Increasing Incidences of Chronic Diseases
• Growing Aging Population
• Advancements in Manufacturing Technologies
• Market Restraints
• Price Controls
• Entry of Biosimilars
• Opportunities
• Untapped Potential in Emerging Markets

Chapter 6 Market Breakdown by Product Type

• Human Protein Replacements
• Market Size and Forecast
• Therapeutic Agents for Human Diseases
• Market Size and Forecast
• Vaccines
• Types of Vaccines
• Market Size and Forecast

Chapter 7 Market Breakdown by End User

• Biotechnology and Pharmaceutical Industry
• Market Size and Forecast
• Research Laboratories and Academic Institutes
• Market Size and Forecast

Chapter 8 Market Breakdown by Region

• Global Market by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 9 Competitive Landscape

• Overview

Chapter 10 Company Profiles

• ABBVIE INC.
• ALEXION PHARMACEUTICALS
• AMGEN INC.
• ELI LILLY
• MERCK & CO. INC.
• SANOFI S.A.
• TAKEDA PHARMACEUTICAL CO LTD.